Daiichi-Sankyo's triple antihypertensive launched in the UK
This article was originally published in Scrip
Executive Summary
Daiichi-Sankyo has launched its triple antihypertensive product Sevikar HCT in the UK, following its decentralised EU approval last year. The product contains the angiotensin II receptor blocker (ARB) olmesartan medoxomil, the calcium channel blocker amlodipine and the diuretic hydrochlorothiazide, and was first launched in Europe late last year in Germany, following its market debut in the US as Tribenzor.